Vertex Pharmaceuticals (VRTX) Short-Term Debt repayments (2017)
Vertex Pharmaceuticals' quarterly Short-Term Debt repayments came in at $300.0 million in Q1 2017.
Vertex Pharmaceuticals has reported Short-Term Debt repayments for 1 years, with the latest figure at $300.0 million in Q1 2017.
- For the quarter ending Q1 2017, Short-Term Debt repayments changed N/A year-over-year to $300.0 million; the trailing twelve-month figure through Dec 2017 stood at $300.0 million (changed N/A YoY), and the FY2017 full-year result was $300.0 million, changed N/A from the prior year.
- Short-Term Debt repayments for Q1 2017 stood at $300.0 million.
- The five-year high for Short-Term Debt repayments was $300.0 million in Q1 2017, with the low at $300.0 million in Q1 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 102,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 31.20 Bn | 31.20 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 300.00 Mn |
| Mar 31, 2017 | 300.00 Mn |